A Phase 2 Prospective Trial of Dabrafenib With Stereotactic Radiosurgery in BRAFV600E Melanoma Brain Metastases

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2013 by University of California, San Francisco
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
Alain Algazi, University of California, San Francisco
ClinicalTrials.gov Identifier:
NCT01721603
First received: November 1, 2012
Last updated: May 9, 2013
Last verified: May 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: October 2015
  Estimated Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)